Metabolic Syndrome – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Metabolic Syndrome – Drugs In Development, 2024 report and make more profitable business decisions.
Metabolic syndrome, also known as insulin resistance syndrome, constitutes a cluster of conditions that collectively heighten the risk of coronary heart disease, diabetes, stroke, and other severe health issues. To be diagnosed with metabolic syndrome, one must exhibit three or more of the following conditions. A significant waistline, termed abdominal obesity or an “apple shape”, indicates a higher risk for heart disease than fat deposits in other body regions. Elevated blood pressure can lead to heart and vascular damage, contributing to plaque buildup in arteries. High blood sugar levels increase the risk of blood clots, potentially causing heart and vascular diseases. Elevated blood triglycerides and low HDL cholesterol levels further amplify the risk. In the US, approximately 1 in 3 adults contend with metabolic syndrome, but it is largely preventable through awareness of risk factors and adopting a healthy lifestyle.
The Metabolic Syndrome drugs in development market research report provide comprehensive information on the therapeutics under development for Metabolic Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metabolic Syndrome and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Metabolic Syndrome | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 28 molecules, with 22 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Metabolic Syndrome therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Metabolic Syndrome pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Metabolic Syndrome treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Alnylam Pharmaceuticals IncAPIE Therapeutics Inc
Bayer AG
Bio-Modeling Systems SAS
Biois Corp
Clearmind Medicine Inc
Defensin Therapeutics ApS
Eolo Pharma
ePurines Inc
Foresee Pharmaceuticals Co Ltd
GB Sciences Inc
Inversago Pharma Inc
Lead Discovery Center GmbH
Medical College of Wisconsin
MediciNova Inc
Palatin Technologies Inc
Renova Therapeutics Inc
Seres Therapeutics Inc
Shanghai Braegen Pharmaceutical Co Ltd
Shanghai Pharmaceuticals Holding Co Ltd
Theriva Biologics Inc
UH Harrington Discovery Institute
University of Colorado Denver
University of Strasbourg
Yale University
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Metabolic Syndrome reports